{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T07:55:19Z","timestamp":1761897319469,"version":"3.33.0"},"reference-count":12,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.com.au","clinicalkey.es","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Leukemia Research"],"published-print":{"date-parts":[[2020,9]]},"DOI":"10.1016\/j.leukres.2020.106406","type":"journal-article","created":{"date-parts":[[2020,6,25]],"date-time":"2020-06-25T15:31:23Z","timestamp":1593099083000},"page":"106406","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"C","title":["Teenage mutant neutrophilic precursors: Leukemia cutis with IDH2 mutation on enasidenib therapy"],"prefix":"10.1016","volume":"96","author":[{"given":"Michael E.","family":"Kallen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rima","family":"Koka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6269-4541","authenticated-orcid":false,"given":"Zeba","family":"Singh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gabriela","family":"Sanchez-Petitto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qamar U.","family":"Zaman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jean A.","family":"Yared","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0278-7727","authenticated-orcid":false,"given":"Vu H.","family":"Duong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.leukres.2020.106406_bib0005","series-title":"World Health Organization Classification of Tumours of Hematopoietic and Lymphoid Tissues","first-page":"167","author":"Swerdlow","year":"2017"},{"key":"10.1016\/j.leukres.2020.106406_bib0010","series-title":"Hematopathology","first-page":"842","article-title":"Chapter 46: acute myeloid leukemia","author":"Arber","year":"2017"},{"issue":"12","key":"10.1016\/j.leukres.2020.106406_bib0015","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1056\/NEJMra1406184","article-title":"Acute myeloid leukemia","volume":"373","author":"D\u00f6hner","year":"2015","journal-title":"N. Engl. J. Med."},{"issue":"7","key":"10.1016\/j.leukres.2020.106406_bib0020","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1177\/2040620718777467","article-title":"The role of enasidenib in the treatment of mutant IDH2 acute myeloid leukemia","volume":"9","author":"Abou Dalle","year":"2018","journal-title":"Ther. Adv. Hematol."},{"issue":"7","key":"10.1016\/j.leukres.2020.106406_bib0025","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1182\/blood-2018-08-869008","article-title":"Molecular remission and response patterns in patients with mutant-IDH2 acute myeloid leukemia treated with enasidenib","volume":"133","author":"Stein","year":"2019","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.leukres.2020.106406_bib0030","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1182\/blood-2017-04-779405","article-title":"Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia","volume":"130","author":"Stein","year":"2017","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.leukres.2020.106406_bib0035","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1182\/blood-2017-04-779447","article-title":"Enasidenib induces acute myeloid leukemia cell differentiation to promote clinical response","volume":"130","author":"Amatangelo","year":"2017","journal-title":"Blood"},{"issue":"18","key":"10.1016\/j.leukres.2020.106406_bib0040","doi-asserted-by":"crossref","first-page":"2777","DOI":"10.1182\/blood-2013-10-512640","article-title":"How we prevent and treat differentiation syndrome in patients with acute promyelocytic leukemia","volume":"123","author":"Sanz","year":"2014","journal-title":"Blood"},{"issue":"27","key":"10.1016\/j.leukres.2020.106406_bib0045","doi-asserted-by":"crossref","first-page":"5512","DOI":"10.1182\/blood-2009-02-204834","article-title":"Chemokine induction by all-trans retinoic acid and arsenic trioxide in acute promyelocytic leukemia: triggering the differentiation syndrome","volume":"114","author":"Luesink","year":"2009","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.leukres.2020.106406_bib0050","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1001\/jamaoncol.2017.4695","article-title":"AG221-C-001 Study Investigators. Differentiation Syndrome Associated With Enasidenib, a Selective Inhibitor of Mutant Isocitrate Dehydrogenase 2: Analysis of a Phase 1\/2 Study","volume":"4","author":"Fathi","year":"2018","journal-title":"JAMA Oncol."},{"issue":"Supplement 1","key":"10.1016\/j.leukres.2020.106406_bib0055","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1182\/blood-2018-99-117426","volume":"132","author":"Norsworthy","year":"2018","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.leukres.2020.106406_bib0060","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1182\/blood-2008-07-168617","article-title":"Differentiation syndrome in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and anthracycline chemotherapy: characteristics, outcome, and prognostic factors","volume":"113","author":"Montesinos","year":"2009","journal-title":"Blood"}],"container-title":["Leukemia Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212620301119?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212620301119?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,1,15]],"date-time":"2025-01-15T22:38:38Z","timestamp":1736980718000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0145212620301119"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9]]},"references-count":12,"alternative-id":["S0145212620301119"],"URL":"https:\/\/doi.org\/10.1016\/j.leukres.2020.106406","relation":{},"ISSN":["0145-2126"],"issn-type":[{"type":"print","value":"0145-2126"}],"subject":[],"published":{"date-parts":[[2020,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Teenage mutant neutrophilic precursors: Leukemia cutis with IDH2 mutation on enasidenib therapy","name":"articletitle","label":"Article Title"},{"value":"Leukemia Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.leukres.2020.106406","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"106406"}}